Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of NYX-458 in Healthy Volunteers

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of NYX-458 in Healthy Volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NYX-458 (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Aptinyx
  • Most Recent Events

    • 30 Apr 2019 Results assessing the safety and pharmacokinetics is published in the Aptinyx Media Release
    • 14 Aug 2018 According to an Aptinyx media release, trial completion expected in first half of 2019.
    • 08 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top